Homepage>Company>Media>Pharma News>2023>Daewoong Pharmaceutical begins the first administration of the Bersiporocin, new treatment for idiopathic pulmonary fibrosis, as Phase II clinical trial
Daewoong Pharmaceutical begins the first administration of the Bersiporocin, new treatment for idiopathic pulmonary fibrosis, as Phase II clinical trial